DataMeds AI, Inc MEDS
3.11
(0.39)
(11.14%)
as of 25 Sep
- Market cap
- $10.9M
- P/E
- 0.0×
Follow MEDS
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — |
P/S ratio |
1.22 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | — |
P/Operating CF |
(4.51) | (68.61) | — |
P/B ratio |
0.00 | 26.73 | — |
Price to Tangible BV |
0.00 | 0.00 | — |
EV/Sales |
2.22 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | — |
EV/Operating CF |
(4.78) | (165.21) | — |
EV/FCF |
(4.42) | (165.21) | — |
Quick Ratio |
0.04 | 0.13 | 0.12 |
Current Ratio |
0.09 | 0.40 | 0.12 |
Net Debt/EBITDA |
(0.30) | (4.44) | (0.12) |
Debt/Assets |
77.11% | 40.78% | 103.43% |
Debt/Equity |
(1.89) | 3.47 | (0.12) |
Asset Turnover |
0.53 | 0.63 | — |
Operating CF/Net income |
0.11 | 0.18 | 0.12 |
Capex/Depreciation |
(0.06) | (0.34) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| 3,545.16% | (357.65%) | 0.00% | |
| (230.71%) | (23.78%) | 0.00% | |
ROIC |
(532.81%) | (13.20%) | 0.00% |
Return on Tangible Assets |
378.86% | 30.49% | 113.54% |
Average Days of Receivables |
17.79 | 75.42 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
306.61% | 37.50% | 0.00% |
Intangible Assets out of Total Assets |
0.80 | 0.64 | 0.00 |
Share Based Compensation of Revenue |
234.79% | 5.96% | — |
Graham Net Nets |
(1.41) | (0.20) | — |
Graham Number |
119.18 | 0.00 | — |
Earnings Yield |
(360.00%) | (3.81%) | — |
Free Cash Flow Yield |
(41.33%) | (0.68%) | — |
Revenue per Share |
16.44 | 19.18 | 0.00 |
Operating CF per Share |
(7.65) | (1.30) | (0.39) |
Capex per Share |
(0.62) | (0.40) | 0.00 |
Free Cash Flow per Share |
(8.27) | (1.70) | (0.39) |
Cash per Share |
0.03 | 1.09 | 0.00 |
Shareholders Equity per Share |
(8.77) | 7.13 | (3.24) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(8.77) | 7.13 | (3.24) |
Free Cash Flow |
(11.74) | (1.60) | (0.35) |
Working Capital |
(26.96) | (22.88) | (2.55) |
Capital Expenditures |
(0.88) | (0.38) | — |
Net Current Asset Value |
(40.09) | (35.43) | (2.90) |
EV/EBIT |
0.00 | 0.00 | — |
Capex to Sales |
0.04 | 0.02 | — |
Net Profit Margin |
(433.95%) | (37.82%) | 0.00% |
Price to Operating Income |
0.00 | 0.00 | — |
| Other line items | |||
Depreciation/Fixed assets |
68.95 | 2.87 | — |
Cash ROIC |
(100.02%) | (5.18%) | 13.70% |
Accounts Receivable Turnover |
9.56 | 8.88 | — |
Accounts Payable Turnover |
3.30 | 4.44 | — |
Inventory Turnover |
5.34 | 0.00 | — |
Average Days of Payables |
143.36 | 141.31 | 0.00 |
Days of Inventory on Hand |
20.10 | 212.35 | — |
Average Receivables |
2.44 | 2.04 | — |
Average Payables |
9.01 | 3.69 | — |
Average Inventory |
5.58 | — | — |
Average Assets |
43.90 | 28.84 | — |
Average Common Equity |
(2.86) | 1.92 | — |
Columns are period end dates